ALERT

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders

The primary objectives of this study were to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder. The study involved 303 participants, recruited from 11 community treatment sites.

CTN Protocol ID:

CTN-0028

DSMB ID:

DSMB-0028

Status:

Completed

ClinicalTrials.gov ID:

Principal Investigator(s)

Paula Riggs, M.D.

University of Colorado School of Medicine

paula.riggs@ucdenver.edu

T. John Winhusen, Ph.D.

Professor of Psychiatry and Behavioral Neuroscience, Director of Addiction Sciences Division

University of Cincinnati

Addiction Sciences Division

3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006
United States

winhust@ucmail.uc.edu

Participating Sites

Addiction Research and Treatment Services (ARTS), Colorado
Western Psychiatric Institute and Clinic (WPIC), Pennsylvania
Rehab After Work - Life Counseling Services, Pennsylvania
Gateway Health Systems, Florida
Operation PAR, Inc., Florida
St. Luke's Roosevelt Hospital Center, New York
Mountain Manor Treatment Programs, Maryland
SSTAR of Rhode Island, Rhode Island
SSTAR of Massachusetts (Stanley Street Treatment & Resources, Inc.), Massachusetts
Lexington/Richland Alcohol and Drug Abuse Council, South Carolina
Mental Health and Mental Retardation of Tarrant County, Texas